JPRN-jRCT2011230029已完成Unknown
33-104 : Drug Use-Results Survey of OPDIVO (Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy)
Kuro Toshihiko0 个研究点目标入组 100 人开始时间: 2023年8月4日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy, who have recieved OPDIVO for the first time
排除标准
- •Patients who have received OPDIVO previously
研究者
相似试验
已完成
Unknown
Drug Use-Results Survey of OPDIVO (Gastric Cancer)Gastric CancerJPRN-jRCT1080224011ONO PHARMACEUTICAL CO.,LTD.500
Unknown
Unknown
Drug Use-Results Survey of OPDIVO (malignant melanoma)Malignant melanomaJPRN-jRCT1080223217ONO PHARMACEUTICAL CO., LTD.1,700
已完成
Unknown
Drug Use-Results Survey of OPDIVO (head and neck cancer)Head and Neck CancerJPRN-jRCT1080224012ONO PHARMACEUTICAL CO.,LTD.400
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma)classical Hodgkin's lymphomaJPRN-jRCT1080224013ONO PHARMACEUTICAL CO.,LTD.250
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (NSCLC)non-small cell lung cancerJPRN-jRCT1080223216ONO PHARMACEUTICAL CO., LTD.1,000